A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
about
Mechanism of action of lenalidomide in hematological malignanciesThe broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillancePP2A: The Achilles Heal in MDS with 5q DeletionThe Basic Biology of PP2A in Hematologic Cells and MalignanciesPP2A: The Wolf in Sheep's Clothing?Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.Ribosomopathies: human disorders of ribosome dysfunction.Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Current therapy of myelodysplastic syndromesSafety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.Non-Diamond Blackfan anemia disorders of ribosome function: Shwachman Diamond syndrome and 5q- syndromeA critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Ribosomopathies: mechanisms of disease.Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.Dose escalation of lenalidomide in relapsed or refractory acute leukemias.Genetic deletions in AML and MDS.New treatments for myelodysplastic syndromesClinical utility of lenalidomide in the treatment of myelodysplastic syndromesTargeting protein tyrosine phosphatases for anticancer drug discovery.Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid LeukemiaClinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromesThe relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromesInitial testing of lenalidomide by the pediatric preclinical testing programMyelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25CCell cycle control in acute myeloid leukemia.Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.The revolution of myelodysplastic syndromes.Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.14-3-3γ Prevents Centrosome Amplification and Neoplastic Progression.
P2860
Q21198872-DA3BB69E-041D-483D-8463-AD2573E7DF6FQ26739246-8E687A67-61FD-4F6E-B956-05407FB73020Q27690852-38C427B6-07D3-457E-AD1A-F7B3C31D78C5Q28088697-37295543-E2BD-4BCA-8189-65617C5E9DE8Q28088747-BA50F6D7-496B-45D0-BAFD-189C50BC1FBAQ30235355-DE726549-0B38-416B-AD92-99D9CB07951AQ33398044-263C4F12-E89C-4A6B-800F-64547B69FE7FQ33408873-D48885E9-CFBA-49FF-AF91-F5C7B0997157Q33595649-E05E1E14-5960-401E-95FA-BDB33430A499Q33780253-D7711964-5F22-4623-B2FA-CD55F013E225Q33806050-060460FA-78A4-481A-8B95-8CDD5646EBB6Q33813750-CF5F4613-D40A-4C76-82CE-4CED812E0477Q34013796-3C209EE8-3BBB-4D94-B472-54C919B106D5Q34060237-6FB47E47-2872-4094-AC13-352493AD151BQ34173140-9511515E-82F6-4C77-94D9-B245DB3D929BQ34220013-2497A260-5F22-47BB-83C6-80B51123B02FQ34342944-F17A3A8A-55DC-41D0-B996-13B3BD3EFD88Q34454066-592C1879-D05B-46CB-9D5B-C8B89F2F46C6Q34483086-563A9C4C-2E33-41DF-BC91-1C7D2DBBEBFEQ34488712-74489725-CF10-4F0A-A60B-28FDE5FB0609Q34545116-12721D5F-5B9D-462F-BC47-9138FDE9DFD1Q34549290-4F04AF4C-6275-458D-AD98-266CCD6752E5Q34783754-6BC7AD87-A63F-474A-AB72-71285BCD3EBAQ34789961-4C822F60-0C6E-4B65-B64A-FCB9328610F0Q35016534-52BF8C9A-8FA7-4717-A098-7F53EB619072Q35037262-C477214F-D17F-4695-8A71-3E344C6EF38CQ35082495-9A045D3E-26A4-49D4-B247-8C2F92A04004Q35125889-F09C4C18-994B-4C0E-A59F-4FAD6E4F65F6Q35171777-A6BA31C5-D5E5-418C-88BF-4E468B072C64Q35182727-60D3336C-FCE8-41F0-934C-ADF65F56EAF0Q35202854-E7358225-15B7-4A61-9D14-C54D61F79085Q35244865-BF847F9C-83E8-4E5B-847D-572F260ACF2FQ35861457-10A83C04-DF79-441E-A519-413D4CF50FDCQ36110604-B38D3C57-F201-4F98-BF62-65C5E987C5FEQ36206479-669A63F1-B85D-4B64-A5EC-22F369E82132Q36417421-9A507714-6CE6-43B8-A53A-C31728FF3BE7Q36474572-9F395141-47A7-44A1-B0B2-8B95B8955AFCQ36612553-783AEA44-2CC2-4176-9F02-A6ECB8963C9FQ36612675-12C6403A-6B24-4476-B1F9-2D6887F98617Q36961022-8550C91D-97C8-4E2A-B4AC-D4B8D6FF6293
P2860
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A critical role for phosphatas ...... letion 5q MDS by lenalidomide.
@en
A critical role for phosphatas ...... letion 5q MDS by lenalidomide.
@nl
type
label
A critical role for phosphatas ...... letion 5q MDS by lenalidomide.
@en
A critical role for phosphatas ...... letion 5q MDS by lenalidomide.
@nl
prefLabel
A critical role for phosphatas ...... letion 5q MDS by lenalidomide.
@en
A critical role for phosphatas ...... letion 5q MDS by lenalidomide.
@nl
P2093
P2860
P356
P1476
A critical role for phosphatas ...... letion 5q MDS by lenalidomide.
@en
P2093
Ann Williams
Gordon Dewald
Jaroslaw Maciejewski
Julie Y Djeu
Kathy Rocha
Lubomir Sokol
Nick Lawrence
P K Epling-Burnette
P2860
P304
12974-12979
P356
10.1073/PNAS.0811267106
P407
P50
P577
2009-05-26T00:00:00Z